Buy analyst ratings: Foreign
2,752 dated buy ratings on 290 Foreign stocks (depositary receipts, New York registry shares and stocks traded over the counter), newest first. The firms' own words in this tab: Buy, Outperform, Overweight. Each row is as the research firm published it in its public rating disclosure. Not investment advice and not a consensus.
- 2026-09-11: Stock LEGN; Price Target $74.00; Price When Rated $19.91; Upside / Downside +271.67%.
- 2026-09-10: Stock BYDDF; Price Target $20.00; Price When Rated $10.73; Upside / Downside +86.39%.
- 2026-09-09: Stock BEIGF; Price Target $415.00; Price When Rated $351.48; Upside / Downside +18.07%.
- 2026-09-09: Stock ONC; Price Target $415.00; Price When Rated $351.48; Upside / Downside +18.07%.
| Date | Stock | Price Target | Price When Rated | Upside / Downside | Analyst | Firm | Rating |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | LEGN Legend Biotech Corp | $74.00 | $19.91 | +271.67% | Etzer Darout | Barclays | Overweight |
| 2026-09-10 | BYDDF BYD CO LTD | $20.00 | $10.73 | +86.39% | Jiong Shao | Barclays | Overweight |
| 2026-09-09 | BEIGF BeOne Medicines Ltd. | $415.00 | $351.48 | +18.07% | Etzer Darout | Barclays | Overweight |
| 2026-09-09 | ONC BeOne Medicines Ltd. | $415.00 | $351.48 | +18.07% | Etzer Darout | Barclays | Overweight |
| 2026-09-08 | TMSOF THOMSON REUTERS CORP /CAN/ | $130.00 | $105.68 | +23.01% | Manav Patnaik | Barclays | Overweight |